Diffuse Large B-cell Lymphoma
Conditions
Keywords
rituximab, everolimus, DLBCL, mTOR
Brief summary
Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies. The purpose of this research study is to determine whether Everolimus plus rituximab is safe and effective in participants with relapsed or refractory DLBCL. Everolimus is an investigational drug that works by blocking a special protein that helps cancer cells grow. The safety and effectiveness of Everolimus in the treatment of DLBCL has not yet been fully determined and is still investigational. The other drug in this study, rituximab, is approved by the US Food and Drug Administration (FDA) for use in patients who have diffuse large B-cell lymphoma and certain other types of non-Hodgkin lymphoma. Rituximab is a drug that destroys both normal and cancerous B-cells.
Detailed description
Participants will receive oral Everolimus and intravenous rituximab for DLBCL that has relapsed or been refractory to prior therapy. * Each treatment cycle lasts 28 days (4 weeks). Everolimus will be taken orally, once daily in the morning. * Rituximab will be administered by an intravenous (IV) infusion on Days 1, 8, 15 and 22 of Cycle 1. In Cycles 2-6, rituximab will be administered only on Day 1 of each cycle. * Participants will come into the clinic weekly during the first cycle, then on Day 1 of all cycles thereafter. The following tests and procedures will be performed: * Weekly During Cycle 1: blood tests * Day 1 of all Subsequent Cycles: brief physical examination; review of current medications, treatments, symptoms and side effects; vital signs; performance status evaluation; blood tests. * A full body CT and PET scan to assess the participants tumor will be done within 7 days of completing cycles 2, 4, 6, 9 and 12. Responding subjects may receive up to 6 cycles of Everolimus plus rituximab, and an additional 6 months of oral Everolimus for participants continuing to respond.
Interventions
DRUGEverolimus
Taken orally once daily in the morning
DRUGrituximab
Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
Sponsors
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Novartis
Massachusetts General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically determined DLBCL that is relapsed or primary refractory after initial therapy * Greater than 1 prior line of chemotherapy (including an anthracycline unless contraindicated) or immunotherapy. Patients must have relapsed after autologous stem cell transplantation, not be eligible for autologous stem call transplantation in the judgment of the investigator, or refuse autologous stem cell transplantation. Salvage chemotherapy and high dose conditioning for autologous stem cell transplantation count as two separate regimens. * Measurable disease that has not been previously irradiated on PET-CT of at least 2cm, OR if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation. Imaging must be completed no greater than 3 weeks from study enrollment. * ECOG performance status 0-2 * 18 years of age or older * Life expectancy of greater than 3 months * Adequate Organ and marrow function * Fasting serum cholesterol of 300 mg/dl or less OR 7.75 mmol/L or less AND fasting triglycerides 2.5 x ULN or less
Exclusion criteria
* Currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of the study drug * Receiving any other investigational agents, or have received investigational agents within 4 weeks of beginning treatment * Major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study * Known leptomeningeal or brain metastases. Imaging or spinal fluid analysis to exclude CNS involvement is not required, unless there is clinical suspicion by the treating investigator * Known HIV infection * Systemic fungal, bacterial, viral, or other infection not controlled * Prior history of malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least one year. Patients with prostate cancer are allowed if PSA is less than 1 * Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period * Severely impaired lung function defined as DLCO of \<60% * Uncontrolled diabetes as defined by fasting serum glucose \> 1.5 x ULN * Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Everolimus * Active bleeding diathesis * Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods * Prior treatment with an mTOR inhibitor * Known hypersensitivity to murine antibodies,everolimus,other rapamycin * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * No chronic treatment with systemic corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are permitted
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | Assessed at the conclusion of cycle 2, cycle 4 and cycle 6 | Complete response plus partial response after 6 cycles. Response rate will be evaluated by using the modified Cheson criteria for lymphoma response. Complete response requires all of the following: 1) PET positive prior to therapy: mass of any size permitted if PET negative. Variable FDG-avid or PET negative prior to therapy: regression to normal size on CT (\</= 1.5cm in their greatest transverse diameter for nodes \>/= 1.5 cm before therapy) 2) Spleen (if enlarged before therapy) must have regressed in size and must not be palpable, 3) If bone marrow is known to be involved, repeat biopsy documents clearance. Partial response requires 1) \>/= 50% decrease in SPD, 2) No new sites of disease or increase in the size of other nodes, liver or spleen, 3) Splenic and hepatic nodules must regress by at least 50% in SPD |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Overall Response | 2 years | Duration of overall response is measured from the time measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented. |
| Progression-free Survival | 2 years | Progression-free survival is defined as the duration of time from start of treatment to time of documentation of progression or death |
Countries
United States
Participant flow
Recruitment details
Patients were recruited in the lymphoma programs of the Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute and Beth-Israel Deaconess Medical Center
Participants by arm
| Arm | Count |
|---|---|
| Treatment Arm All patients received treatment with everolimus-rituximab on this single am study | 25 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | removed prior to starting therapy | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Treatment Arm |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 13 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants |
| Region of Enrollment United States | 25 participants |
| Sex: Female, Male Female | 10 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 24 / 24 |
| serious Total, serious adverse events | 6 / 24 |
Outcome results
Primary
Overall Response Rate
Complete response plus partial response after 6 cycles. Response rate will be evaluated by using the modified Cheson criteria for lymphoma response. Complete response requires all of the following: 1) PET positive prior to therapy: mass of any size permitted if PET negative. Variable FDG-avid or PET negative prior to therapy: regression to normal size on CT (\</= 1.5cm in their greatest transverse diameter for nodes \>/= 1.5 cm before therapy) 2) Spleen (if enlarged before therapy) must have regressed in size and must not be palpable, 3) If bone marrow is known to be involved, repeat biopsy documents clearance. Partial response requires 1) \>/= 50% decrease in SPD, 2) No new sites of disease or increase in the size of other nodes, liver or spleen, 3) Splenic and hepatic nodules must regress by at least 50% in SPD
Time frame: Assessed at the conclusion of cycle 2, cycle 4 and cycle 6
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Everolimus/Rituximab | Overall Response Rate | 38 percentage of participants |
Secondary
Duration of Overall Response
Duration of overall response is measured from the time measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented.
Time frame: 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Everolimus/Rituximab | Duration of Overall Response | 8.1 months |
Secondary
Progression-free Survival
Progression-free survival is defined as the duration of time from start of treatment to time of documentation of progression or death
Time frame: 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Everolimus/Rituximab | Progression-free Survival | 2.9 months |